您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > Carvedilol phosphate hemihydrate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Carvedilol phosphate hemihydrate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Carvedilol phosphate hemihydrate图片
CAS NO:610309-89-2
包装与价格：
包装价格(元)
100mg电议
500mg电议

产品介绍
Carvedilol (phosphate hemihydrate) (BM 14190 (phosphate hemihydrate)) 是非选择性 β 和 α1 阻断剂, 能抑制 LDL 的氧化, IC50为 3.8 μM。
Cas No.610309-89-2
别名卡维地洛磷酸盐,BM 14190 phosphate hemihydrate
Canonical SMILESO=P(OO)=O.OC(CNCCOC1=CC=CC=C1OC)COC2=CC=CC(N3)=C2C4=C3C=CC=C4.[HH].[0.5H2O]
分子式C24H26N2O4. H3PO4.1/2H2O
分子量513.48
溶解度Soluble in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Carvedilol (phosphate hemihydrate) (BM 14190 (phosphate hemihydrate)) is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation. IC50: 3.8 μM (beta Adrenergic Receptor).

Carvedilol (BM 14190) is a nonselective-blocking agent and is used in the treatment of hypertension and angina pectoris. As a third-generation β-adrenergic blocker (β-blocker), Carvedilol is able to reverse cardiac structural remodeling. Recentresults demonstrated that the effect caused by Carvedilol on cardiac remodeling is largely dependent on endogenous NO.

[1]. Chen J, et al. The effects of carvedilol on cardiac structural remodeling: The role of endogenous nitric oxide in the activity of carvedilol. Mol Med Rep. 2013 Apr;7(4):1155-1158. [2]. Stafylas PC, et al. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30. [3]. Othman AA, et al. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007 Jun 15;9(2):E208-18. [4]. Koshimizu TA, et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-672.